55Co-PSMA-617

55Co-PSMA-617 is an investigational radiopharmaceutical developed as a positron emission tomography (PET) imaging agent for the detection and staging of prostate cancer. It consists of the small-molecule ligand PSMA-617 (vipivotide tetraxetan), which specifically binds to the prostate-specific membrane antigen (PSMA) overexpressed on prostate cancer cells, labeled with the positron-emitting radioisotope cobalt-55 (55Co). Cobalt-55 is utilized due to its relatively long half-life of approximately 17.5 hours, which is significantly longer than common PET isotopes like gallium-68 (68 minutes) or fluorine-18 (110 minutes). This extended half-life allows for delayed imaging (up to 24-48 hours post-injection), potentially providing higher tumor-to-background contrast and improved detection of small metastatic lesions by allowing more time for tracer accumulation in tumors and clearance from non-target tissues. The agent is primarily being evaluated in academic clinical trials for its diagnostic utility in patients with primary or metastatic prostate cancer.

Other names

Co-PSMAcobalt-55 PSMA-617cobalt55 PSMA-617cobalt 55 PSMA-617cobalt-55-labeled PSMA-617cobalt55-labeled PSMA-617cobalt 55-labeled PSMA-61755Co-vipivotide tetraxetan